Seelos Therapeutics, Inc (SEEL)

Etorro trading 970x250
Seelos Therapeutics, Inc (SEEL) Logo

About Seelos Therapeutics, Inc

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company’s lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorder and post-traumatic stress disorder; SLS-005, a protein stabilizer for the treatment of Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson’s disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York. Address: 300 Park Avenue, New York, NY, United States, 10022

Seelos Therapeutics, Inc News and around…

Latest news about Seelos Therapeutics, Inc (SEEL) common stock and company :

iX Biopharma Signs Exclusive License Agreement For Wafermine And Other Sublingual Ketamine Wafer Products
24 Nov, 2021 Yahoo! Finance

iX Biopharma Ltd (SGX:42C), a specialty pharmaceutical company that develops innovative therapies using its proprietary sublingual drug delivery technology, WaferiX, announced today that it has, through its subsidiary, entered into an exclusive license agreement with Seelos Therapeutics, Inc ("Seelos") (Nasdaq: SEEL), a company focused on developing novel therapeutics for central nervous systems disorders. Under the agreement, iX Biopharma will license to Seelos its lead drug under development,

Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma's Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine
24 Nov, 2021 Yahoo! Finance

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it has entered into an exclusive license agreement (License Agreement), whereby it acquired a worldwide license (excluding China, Taiwan, Macau and Hong Kong) from iX Biopharma Ltd (iX Biopharma) for Wafermine™, a sublingual racemic ketamine wafer, and a worldwide license for other sublingual ketamine

Seelos Therapeutics Raises $20 Million in Private Placement of Senior Secured Convertible Note
24 Nov, 2021 Yahoo! Finance

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced the placement of a $22.0 million senior secured convertible note (the "Note") and shares of Seelos common stock (the "Closing Shares") to Lind Global Asset Management V, LLC, managed by The Lind Partners, a New York institutional fund manager and an existing investor in Seelos. Seelos will receive $20.

Singapore Based iX Biopharma Hands Seelos Exclusive Rights For Wafermine For Pain Management
24 Nov, 2021 FinancialContent

iX Biopharmahasinked an exclusive agreementto license its lead drug under development, Wafermine, toSeelos ...

10 Stock Picks of Nathaniel August’s Mangrove Partners
23 Nov, 2021 Yahoo! Finance

In this article, we will discuss 10 stock picks of Nathaniel August’s Mangrove Partners. If you want to skip our detailed analysis of these stocks, you can go directly to the 5 Stock Picks of Nathaniel August’s Mangrove Partners. Nathaniel August founded Mangrove Partners in April 2010 and now serves as the President of the […]

10 Top Penny Stocks To Watch With Potential Biotech Catalysts This Week
14 Nov, 2021 FinancialContent
Seelos Therapeutics to Present at the 4th Annual ALS ONE Research Symposium
10 Nov, 2021 Yahoo! Finance

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it has been selected to present at the 4th Annual ALS ONE Research Symposium, November 29-30th, 2021.

Could The Seelos Therapeutics, Inc. (NASDAQ:SEEL) Ownership Structure Tell Us Something Useful?
09 Nov, 2021 Yahoo! Finance

If you want to know who really controls Seelos Therapeutics, Inc. ( NASDAQ:SEEL ), then you'll have to look at the...

Seelos Therapeutics To Test Trehalose In Patients With Rare Movement Control Disorder
08 Nov, 2021 FinancialContent

TheFDA has acceptedSeelos Therapeutics Inc's(NASDAQ: SEEL) Investigation New Drug application to study SLS-005 ...

Seelos Therapeutics Announces FDA Acceptance of Investigational New Drug Application and Grant of Fast Track Designation for SLS-005 (IV Trehalose) for the Treatment of Spinocerebellar Ataxia
08 Nov, 2021 Yahoo! Finance

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted Seelos' Investigation New Drug (IND) application to study SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) for the treatment of spinocerebellar ataxia (SCA). The FDA has also granted the program Fast Track designation in th

Psychedelics Offer Hope for Mental Disorders, Addiction
03 Nov, 2021 FinancialContent
Seelos Therapeutics to Participate in Two Investor Conferences
02 Nov, 2021 Yahoo! Finance

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the Guggenheim Healthcare Talks, Idea Forum, 3rd Annual Neuro/Immunology Day on November 15-16th and in The Benchmark Company 10th Annual Discovery One on One Investor Conference on December 2nd, 2021.

Are These Trending Penny Stocks on Your Watchlist Right Now?
28 Oct, 2021 FinancialContent
Biotech Companies Are Embracing the Growing Psychedelic Drug Market To Confront a Global Increase in Depression and Anxiety
27 Oct, 2021 FinancialContent

Image by 3D Animation Production Company from Pixabay The following post was written and/or published as a collaboration between ...

Seelos Therapeutics Presents a Poster on SLS-002 (Intranasal Racemic Ketamine) at the 2021 IASR/AFSP International Summit on Suicide Research
25 Oct, 2021 Yahoo! Finance

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today presented a poster on Part 1, the open-label portion, of the study of SLS-002 (Intranasal Racemic Ketamine) at the IASR/AFSP International Summit on Suicide Research Virtual Conference.

3 Biotech Penny Stocks to Watch That Are Climbing Right Now
22 Oct, 2021 FinancialContent
Are These Penny Stocks on Your Watchlist Right Now?
21 Oct, 2021 FinancialContent
B. Riley Sees 'Significant Potential' In This Beaten-Up Biotech Stock
21 Oct, 2021 FinancialContent

B. Riley analyst callsSeelos Therapeutics Inc(NASDAQ: SEEL) his top "Battered Bastions" pick with the stock ...

Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
18 Oct, 2021 FinancialContent

The Week In Psychedelics Atai Launches ‘Precision Psychiatry’ Subsidiary The Psychedelics Sector ...

First Week of SEEL December 17th Options Trading
15 Oct, 2021 FinancialContent

Investors in Seelos Therapeutics Inc (SEEL) saw new options become available this week, for the December 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SEEL options chain for the new December 17th contracts and identified the following call contract of particular interest.

Forget The Hype: The Psychedelic Stocks Sector Went Down In The Third Quarter Of 2021
15 Oct, 2021 FinancialContent

Despite the prevailing hype, the psychedelic sector went down considerably last quarter (July through September) and has gone down even further so far this month.

Rising Acceptance For Treating Mental Disorders is Fueling Strong Growth in Psychedelic Drugs Market
14 Oct, 2021 FinancialContent
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
13 Oct, 2021 FinancialContent

Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking ...

Top Penny Stocks to Know in Mid-October 2021? 3 to Watch
12 Oct, 2021 FinancialContent
Why North America Region is Dominating the Billion Dollar Psychedelic Drugs Market
05 Oct, 2021 FinancialContent
COVID Tests, THC Patches, Psychedelics: Xphyto Therapeutics Does it All
04 Oct, 2021 FinancialContent

Image by Shameer Pk from Pixabay From 25-minute COVID-19 lab tests to psychedelic medicine that is poised to address mental health ...

September Summary: Cannabis-Based Vs. Psychedelic Compounds-Based Drug Stock Performances
02 Oct, 2021 FinancialContent

Which index out-performed in September, the Pure-Play Marijuana-Based Drug Stocks Index or the Pure-Play Psychedelic Compounds-Based Drug Stocks Index?

Seelos Therapeutics to Present a Poster on SLS-002 (Intranasal Racemic Ketamine) at the 2021 IASR/AFSP International Summit on Suicide Research
01 Oct, 2021 Yahoo! Finance

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it has been selected to present a poster on SLS-002 (Intranasal Racemic Ketamine) at the IASR/AFSP International Summit on Suicide Research Virtual Conference, October 24-27th, 2021.

Hot Penny Stocks That Investors on Reddit Are Watching Right Now
29 Sep, 2021 FinancialContent
Psychedelics Called the ‘Next Frontier’ for Investors, Also Offer Promising Treatments
29 Sep, 2021 FinancialContent

Seelos Therapeutics, Inc (SEEL) is a NASDAQ Common Stock listed in , ,

970x250